Basic Glucophage SR Information

• INN (International Nonproprietary Name): Metformin hydrochloride (Metforminum hydrochloridum).
• Brand Names Available In United Kingdom: Glucophage SR and equivalent metformin extended‑release generics (brand examples in EU include Metformin STADA SR and Metformin Teva SR; specific UK marketing authorisations not specified).
• ATC Code: A10BA02 (Metformin; classified under A10B Blood Glucose Lowering Drugs, Excluding Insulins; A10BA Biguanides).
• Forms & Dosages: Extended‑release tablets available in 500 mg, 750 mg and 1000 mg strengths for once‑daily oral administration.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: Prescription Medicine (Rx only) in major markets.

Key Findings From Recent Trials

Major 2022–2025 Studies

Patients and clinicians ask whether metformin remains the sensible first choice for type 2 diabetes.

Large meta‑analyses and pragmatic trials from 2022–24 consistently reaffirm metformin as first‑line therapy when added to lifestyle measures.

Extended‑release formulations such as Glucophage SR and Glucophage XR were included in pooled analyses alongside immediate‑release preparations.

Main Outcomes

Across trials the average HbA1c reduction when starting metformin alongside diet and exercise is around 0.8–1.1%.

Weight change is generally neutral or shows slight loss compared with sulfonylureas in comparative analyses.

Real‑world observational cohorts suggest earlier initiation is associated with lower all‑cause cardiovascular events, though randomised cardiovascular outcome trials specifically powered for metformin are limited.

Extended‑release metformin delivers glycaemic control similar to immediate‑release formulations while supporting once‑daily dosing.

Safety Observations

Gastrointestinal side effects are the commonest adverse events but are reduced with SR formulations because of lower plasma peaks.

Lactic acidosis remains extremely rare when renal function is assessed and monitored appropriately.

Long‑term therapy is associated with reductions in vitamin B12 levels in some patients and periodic monitoring is reasonable.

UK guidance continues to position metformin as first‑line pharmacotherapy in most adults with type 2 diabetes.

Clinical Mechanism Of Action

Layman’s Explanation

Most people worry about how the tablet actually lowers blood sugar.

Metformin works mainly by reducing the amount of glucose the liver releases into the bloodstream and by making the body respond better to its own insulin.

Extended‑release tablets release the active ingredient slowly to reduce stomach upset while keeping blood glucose steady overnight and through the day.

Scientific Breakdown

The drug exerts three predominant pharmacodynamic effects: inhibition of hepatic gluconeogenesis, modest improvement of peripheral insulin sensitivity, and changes in intestinal glucose handling and microbiota composition.

Hepatic Effects

Metformin reduces activity of mitochondrial respiratory chain complex I in hepatocytes which lowers ATP production and shifts cellular energy balance.

This leads to activation of AMP‑activated protein kinase (AMPK) and suppression of gluconeogenic gene expression, reducing hepatic glucose output.

Peripheral Effects

Enhanced insulin signalling in muscle and adipose tissue increases glucose uptake, although this is a secondary and generally modest effect compared with the hepatic action.

Gut‑Mediated Mechanisms

Extended‑release metformin produces local intestinal effects that include increased GLP‑1 secretion and measurable changes in gut microbiota that may contribute to glycaemic improvement and tolerability.

The delayed absorption profile of SR tablets is part of this gut‑mediated mechanism and helps blunt peak plasma concentrations that cause GI symptoms.

Pharmacokinetics of SR tablets support once‑daily dosing with steadier plasma levels compared with immediate‑release forms.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Metformin hydrochloride in extended‑release form is licensed as an oral glucose‑lowering agent for type 2 diabetes in adults.

Brand names internationally include Glucophage SR and Glucophage XR, with equivalent generics available across the EU and other markets.

NICE and other international guidelines recommend metformin as first‑line pharmacotherapy alongside lifestyle measures for newly diagnosed type 2 diabetes.

Notable Off‑Label Trends

Clinicians sometimes prescribe metformin off‑label for insulin resistance syndromes such as polycystic ovary syndrome (PCOS).

Use in prediabetes occurs when lifestyle measures have failed, although formal licencing for prediabetes varies.

Extended‑release products have limited paediatric data and are generally not indicated for children under 18 years in the SR form.

In pregnancy metformin is used under specialist oversight for gestational diabetes or PCOS in selected cases after a multidisciplinary risk–benefit discussion.

Dosage Strategy

General Dosing

Start with a cautious approach to reduce early adverse effects and support adherence.

Begin Glucophage SR at 500 mg once daily with the evening meal to reduce gastrointestinal symptoms.

Titrate by roughly 500 mg weekly as tolerated to the effective dose.

Maintenance dosing is commonly between 1000 mg and 2000 mg once daily depending on product labelling and clinical response.

Some SR products permit up to 2500 mg/day according to specific brand labelling, but many formularies set 2000 mg/day as the conventional maximum.

Condition‑Specific Dosing

Type 2 Diabetes (Adults): start 500 mg once daily and increase to 500 mg twice daily or switch to higher‑strength SR once daily as needed to reach target glycaemic response within weeks.

Elderly Patients: use lower starting doses and monitor renal function and creatinine frequently while titrating carefully.

Renal Impairment: do not start metformin if eGFR is 30–45 mL/min/1.73 m² without specialist review.

Renal Impairment: metformin is contraindicated where eGFR is below 30 mL/min/1.73 m².

Paediatrics: SR formulations are generally not indicated for children under 18 years per available data.

Missed Dose Guidance: take the missed dose when remembered unless it is near the time for the next dose; do not double up.

Safety Protocols

Contraindications

Absolute contraindications include severe renal impairment with eGFR under 30 mL/min/1.73 m².

Other absolutes are known hypersensitivity to metformin or excipients, acute or chronic metabolic acidosis including diabetic ketoacidosis, and recent or ongoing tissue hypoxia such as in cardiac or respiratory failure or shock.

Excessive alcohol consumption and active alcoholism are also contraindications due to risk of lactic acidosis.

Use with caution or avoid in significant hepatic impairment because of heightened lactic acidosis risk.

Age over 80 years requires documented normal renal function before starting therapy.

Adverse Effects

Gastrointestinal symptoms are the commonest adverse effects and include nausea, diarrhoea, abdominal pain, flatulence and reduced appetite.

These symptoms are usually transient and improve with gradual titration or switching to an SR formulation.

Long‑term metformin therapy may reduce vitamin B12 levels; consider monitoring every 1–2 years or sooner if symptoms such as anaemia or neuropathy develop.

Lactic acidosis is very rare but serious; stop metformin and seek urgent care if patients develop unexplained malaise, myalgia or respiratory distress.

Baseline and periodic monitoring should include renal function (eGFR) and clinical review around intercurrent illnesses, dehydration or contrast imaging procedures.

Interaction Mapping

Food Interactions

Take Glucophage SR with the evening meal to reduce peak gastrointestinal effects.

There is no clinically relevant food interaction that reduces efficacy, but avoid large amounts of alcohol which increases lactic acidosis risk.

Drug Combinations To Avoid

Iodinated Contrast Media: withhold metformin temporarily around contrast procedures for patients with risk factors or reduced eGFR and check renal function before restarting.

Nephrotoxic Agents: concurrent use of NSAIDs, ACE inhibitors, ARBs or diuretics requires renal monitoring and dose review.

Drugs That Increase Metformin Levels: cimetidine and some anti‑infectives can raise metformin plasma concentrations and warrant closer monitoring.

Hypoglycaemia Risk Combinations: sulfonylureas and insulin increase the risk of hypoglycaemia when combined with metformin; educate patients and consider dose reductions.

Trimethoprim and other renally excreted drugs can alter clearance and require caution and review of renal function.

Stop metformin during acute dehydration, severe infection or when patients are fasting for procedures unless advised otherwise by clinicians.

Patient Experience Analysis

Survey Data

Patients commonly ask whether switching to SR will help with nausea and diarrhoea.

Surveys and real‑world adherence studies favour extended‑release metformin for improved tolerability and convenience.

Primary‑care audits in the UK report higher continuation rates for once‑daily SR formulations compared with twice‑daily immediate‑release tablets.

Most patients report initial GI upset during titration that settles with time or after switching to SR.

Forum Trends

Online forums show that many people value the once‑daily dosing and report weight stabilisation rather than gain.

Common concerns raised include long‑term vitamin B12 deficiency and occasional persistent GI complaints that may require alternative therapy.

Patients appreciate affordability of generics and clearer guidance about renal monitoring, but some remain confused about holding metformin for contrast scans.

These patient narratives highlight the need for clear counselling on titration, monitoring and peri‑procedural instructions to improve adherence.

Distribution & Pricing Landscape

Where patients can obtain Glucophage SR and equivalent metformin SR tablets is a frequent practical question.

Glucophage SR and generic ER formulations are supplied by multiple manufacturers worldwide including Sanofi, Teva, STADA, Zentiva and Medochemie among others.

Packaging varies by market and includes blister packs and cartons in counts such as 30, 60 and 120 tablets, with common strengths of 500 mg and 750 mg and 1000 mg in some markets.

In the United Kingdom NHS prescriptions favour generics for cost‑effectiveness and generics are substantially cheaper than branded ER products.

Online pharmacies require a valid prescription, and patients should use regulated UK pharmacies when possible to ensure standards of supply and packaging.

In our online pharmacy, glucophage sr is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Supply trends show increasing availability of generic ER products, competitive pricing and generally stable supply chains.

Alternative Options

Comparison Table

The table below summarises common comparator classes and practical trade‑offs to discuss with patients.

• Metformin SR: First‑line, well established, weight neutral, once‑daily SR improves adherence; GI side effects and B12 risk are main downsides.
• SGLT2 Inhibitors: Offer cardio‑renal benefits and weight loss but cost more and increase genital infection risk.
• DPP‑4 Inhibitors: Well tolerated, weight neutral, but produce smaller HbA1c reductions and are costlier than generics.
• Sulfonylureas: Potent glucose lowering but increased hypoglycaemia risk and weight gain limit use for some.
• GLP‑1 Receptor Agonists: Significant weight loss and cardiovascular benefits for some, but are injectable and expensive.

Pros And Cons

Choice of therapy depends on comorbidities, renal function, cost, patient preference and tolerability.

Metformin SR remains the practical first choice for many patients starting pharmacotherapy for type 2 diabetes.

Regulatory Status

Metformin hydrochloride is classified under ATC A10BA02 and recognised widely as a biguanide glucose‑lowering agent.

Glucophage SR, Glucophage XR and generic metformin ER products have regulatory approvals across multiple jurisdictions including EU member state registrations and FDA approvals for ER formulations in the USA.

Romanian regulatory listings document Glucophage SR packaging approvals and public entries in national databases.

Across major markets metformin SR is prescription‑only and product labelling uniformly highlights renal assessment, peri‑procedural withholding for iodinated contrast in at‑risk patients, and B12 monitoring considerations.

Generic SR formulations are approved via bioequivalence pathways and remain subject to post‑marketing surveillance for rare events such as lactic acidosis.

Consolidated FAQ

Q: Is Glucophage SR available in the UK?

A: Yes — metformin SR formulations such as Glucophage SR and generics are supplied in many markets and available by prescription; common strengths include 500 mg, 750 mg and 1000 mg SR in some countries.

Q: How quickly does it work?

A: Fasting glucose can improve within days, while meaningful changes in HbA1c typically appear over weeks to months.

Q: What if I miss a dose?

A: Take the missed dose when you remember unless it is close to the next scheduled dose; do not double up.

Q: Can I drink alcohol?

A: Avoid excess alcohol because it increases the risk of lactic acidosis.

Q: Do I need blood tests?

A: Baseline and periodic renal function checks (eGFR) are essential, and consider B12 testing during long‑term therapy or if symptoms suggest deficiency.

Q: Can pregnant women use metformin SR?

A: Metformin is used in pregnancy under specialist care for gestational diabetes or PCOS in some cases; discuss with the maternity team.

Q: When should it be stopped?

A: Stop for acute dehydration, severe infection, planned contrast imaging when at risk, or if eGFR falls below contraindicated thresholds; seek clinician advice.

Visual Guide

Suggested Graphics

Tablet And Packaging Imagery

Include high‑resolution images of SR tablets and typical packaging variants (500 mg, 750 mg and 1000 mg blisters/cartons) with clear labelling to help patient recognition.

Dosing Flowchart

Provide a simple flowchart illustrating initiation (500 mg with evening meal), weekly titration steps and decision points for switching strengths or stopping for side effects.

Renal Decision Tree

Offer a renal function decision tree with clear eGFR bands: >45 mL/min/1.73 m² (standard use), 30–45 mL/min/1.73 m² (specialist review before initiation), <30 mL/min/1.73 m² (contraindicated).

Design notes: use NHS‑style wording, metric units, strong colour contrast and alt text for accessibility.

Storage And Transport

Store Glucophage SR tablets at room temperature between 15–30°C in a dry place and keep in original packaging.

Do not refrigerate or expose tablets to excessive heat or moisture as this can affect release characteristics.

Pharmacies should maintain dry, temperature‑controlled conditions during distribution and avoid prolonged sunlight exposure.

Patients collecting medication should keep blister packs intact until use and avoid transferring tablets into unlabelled containers.

For travel, advise patients to carry a copy of the prescription and the patient information leaflet and to check customs regulations before travelling with medication.

Dispose of expired or unwanted tablets at a pharmacy for safe disposal rather than throwing them away in household waste.

Guidelines For Proper Use

Before starting confirm the indication for type 2 diabetes and check baseline renal function (eGFR).

Assess hepatic function and alcohol intake and document any contraindications such as eGFR under 30 mL/min/1.73 m².

Commence Glucophage SR at 500 mg once daily with the evening meal and explain weekly titration of around 500 mg as tolerated.

Advise patients about common GI side effects and what to do if they occur, including contacting the practice if symptoms persist.

Instruct patients to stop metformin during acute illness causing dehydration, before procedures involving contrast dye where renal risk exists, or on advice of the clinician.

Arrange follow‑up renal checks within 1–3 months after initiation and periodically thereafter, and consider B12 testing in long‑term users or those with anaemia or neuropathy.

If combined with sulfonylurea or insulin, counsel on hypoglycaemia recognition and having a glucose source available.

Delivery Across United Kingdom